<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="10229">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00681109</url>
  </required_header>
  <id_info>
    <org_study_id>07-07-047</org_study_id>
    <nct_id>NCT00681109</nct_id>
  </id_info>
  <brief_title>Topical IL-1-Ra for Treatment of Posterior Blepharitis</brief_title>
  <official_title>Safety and Efficacy of Topical Interleukin-1-Receptor Antagonist in the Treatment of Signs and Symptoms of Posterior Blepharitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts Eye and Ear Infirmary</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts Eye and Ear Infirmary</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effectiveness and safety of Topical
      Interleukin-1-Receptor Antagonist in treatment of signs and symptoms of posterior
      blepharitis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Meibomian Gland Secretion Quality</measure>
    <time_frame>16 Weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Tear Breakup Time (TBUT)</measure>
    <time_frame>16 Weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Cornea Staining Score</measure>
    <time_frame>16 Weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Conjunctival Staining Score</measure>
    <time_frame>16 Weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Ocular Surface Disease Index (OSDI)</measure>
    <time_frame>16 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The Ocular Surface Disease Index (OSDI) is a 12-item questionnaire designed to provide a rapid assessment of the symptoms of ocular irritation consistent with dry eye disease and their impact on vision-related functioning. The 12 items of the OSDI questionnaire are graded on a scale of 0 to 4, where 0 indicates none of the time; 1, some of the time; 2, half of the time; 3, most of the time; and 4, all of the time. The total OSDI score is then calculated on the basis of the following formula: OSDI=[(sum of scores for all questions answered) x 100]/[(total number of questions answered) x 4].
Thus, the OSDI is scored on a scale of 0 to 100, with higher scores representing greater disability. A negative change from baseline indicated an improvement in vision-related functioning.
OSDI was assessed on the Screening Visit, Week 2, Week 6, Week 12, Week 16. Change indicated represents change from Screening to Week 12.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Meibomian Gland Occlusion</measure>
    <time_frame>16 Weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Schirmer Without Anesthesia</measure>
    <time_frame>16 Weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Schirmer With Anesthesia</measure>
    <time_frame>16 Weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Adverse Events</measure>
    <time_frame>16 Weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Posterior Blepharitis</condition>
  <arm_group>
    <arm_group_label>Treatment Arm 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2.5% IL-1Ra</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Artificial Tear</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Arm 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5% IL-1Ra</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2.5% IL-1Ra</intervention_name>
    <description>2.5% custom made topical IL-1Ra three times a day in both eyes for three months</description>
    <arm_group_label>Treatment Arm 1</arm_group_label>
    <other_name>Anakinra 2.5%</other_name>
    <other_name>Kineret 2.5%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>custom eye drop to be applied three times a day in both eyes for three months</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Artificial Tear</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5% IL-1Ra</intervention_name>
    <description>5% custom made topical IL-1Ra to both eyes 3 times a day for 3 months</description>
    <arm_group_label>Treatment Arm 2</arm_group_label>
    <other_name>Anakinra 5%</other_name>
    <other_name>Kineret 5%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A diagnosis of posterior blepharitis

          -  A negative urine pregnancy test result for women of childbearing potential

          -  Women of childbearing potential must agree to use adequate contraception (hormonal or
             barrier method of birth control) prior to study entry and for the duration of study
             participation

          -  Normal lid position and closure

          -  Ability to understand and provide informed consent to participate in this study

          -  Willingness to follow study instructions and likely to complete all required visits.

        Exclusion Criteria:

          -  History of Stevens-Johnson syndrome or ocular pemphigoid

          -  History of eyelid surgery

          -  Intra-ocular surgery or ocular laser surgery within 3 months

          -  History of microbial keratitis, including herpes

          -  Active ocular allergies

          -  Corneal epithelial defect &gt; 1mm2

          -  Use of topical steroids or Restasis within the past 2 weeks

          -  Use of tetracycline compounds (tetracycline, doxycycline, and minocycline) within the
             last month

          -  Use of isotretinoin (Accutane) within the past 6 months

          -  Have had any previous treatment with Anakinra (KineretÂ®) or any therapeutic agent
             targeted at IL-1 blockade

          -  Pregnant or lactating women

          -  Signs of current infection, including fever and current treatment with antibiotics

          -  Liver, renal, or hematologic disease

          -  The use of any other investigational drug
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reza Dana, MD, MPH, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts Eye and Ear Infirmary</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>December 2012</verification_date>
  <lastchanged_date>December 7, 2012</lastchanged_date>
  <firstreceived_date>May 19, 2008</firstreceived_date>
  <firstreceived_results_date>December 19, 2011</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Blepharitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>2.5% IL-1Ra</title>
          <description>Anakinra (IL-1Ra) 2.5% Topical Ophthalmic Solution three times per day.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Artificial Tear Topical Ophthalmic Solution three times per day.</description>
        </group>
        <group group_id="P3">
          <title>5% IL-1Ra</title>
          <description>Anakinra (IL-1Ra) 5% Topical Ophthalmic Solution three times per day.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>2.5% IL-1Ra</title>
          <description>Anakinra 2.5% Topical Ophthalmic Solution</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Artificial Tear Topical Ophthalmic Solution</description>
        </group>
        <group group_id="B3">
          <title>5% IL-1Ra</title>
          <description>Anakinra 5% Topical Ophthalmic Solution</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="30"/>
                <measurement group_id="B2" value="30"/>
                <measurement group_id="B3" value="15"/>
                <measurement group_id="B4" value="75"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="25"/>
                <measurement group_id="B2" value="24"/>
                <measurement group_id="B3" value="7"/>
                <measurement group_id="B4" value="56"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
                <measurement group_id="B2" value="6"/>
                <measurement group_id="B3" value="8"/>
                <measurement group_id="B4" value="19"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="49" spread="14"/>
                <measurement group_id="B2" value="53" spread="12"/>
                <measurement group_id="B3" value="58" spread="16"/>
                <measurement group_id="B4" value="52" spread="14"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="18"/>
                <measurement group_id="B2" value="16"/>
                <measurement group_id="B3" value="10"/>
                <measurement group_id="B4" value="44"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="12"/>
                <measurement group_id="B2" value="14"/>
                <measurement group_id="B3" value="5"/>
                <measurement group_id="B4" value="31"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="30"/>
                <measurement group_id="B2" value="30"/>
                <measurement group_id="B3" value="15"/>
                <measurement group_id="B4" value="75"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Meibomian Gland Secretion Quality</title>
        <time_frame>16 Weeks</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tear Breakup Time (TBUT)</title>
        <time_frame>16 Weeks</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cornea Staining Score</title>
        <time_frame>16 Weeks</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Conjunctival Staining Score</title>
        <time_frame>16 Weeks</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ocular Surface Disease Index (OSDI)</title>
        <description>The Ocular Surface Disease Index (OSDI) is a 12-item questionnaire designed to provide a rapid assessment of the symptoms of ocular irritation consistent with dry eye disease and their impact on vision-related functioning. The 12 items of the OSDI questionnaire are graded on a scale of 0 to 4, where 0 indicates none of the time; 1, some of the time; 2, half of the time; 3, most of the time; and 4, all of the time. The total OSDI score is then calculated on the basis of the following formula: OSDI=[(sum of scores for all questions answered) x 100]/[(total number of questions answered) x 4].
Thus, the OSDI is scored on a scale of 0 to 100, with higher scores representing greater disability. A negative change from baseline indicated an improvement in vision-related functioning.
OSDI was assessed on the Screening Visit, Week 2, Week 6, Week 12, Week 16. Change indicated represents change from Screening to Week 12.</description>
        <time_frame>16 Weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>The OSDI analysis for this study is based on a standard intention-to-treat analysis with each study participant analyzed with respect to the randomized treatment assignment, regardless of eventual compliance.</population>
        <group_list>
          <group group_id="O1">
            <title>Anakinra 2.5% Topical Ophthalmic Solution</title>
            <description>In this study, the OSDI was assessed for patients taking Anakinra (KINERET) 2.5%. The outcome presented is a number that represents the percent change in OSDI score from baseline to week 12.</description>
          </group>
          <group group_id="O2">
            <title>Artificial Tear Topical Ophthalmic Solution</title>
            <description>The OSDI was assessed for patients taking placebo. The outcome presented is a number that represents the percent change in OSDI score from baseline to week 12.</description>
          </group>
          <group group_id="O3">
            <title>Anakinra 5% Topical Ophthalmic Solution</title>
            <description>The OSDI was assessed for patients taking Anakinra (KINERET) 5%. The outcome presented is a number that represents the percent change in OSDI score from baseline to week 12.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="30"/>
                  <measurement group_id="O2" value="30"/>
                  <measurement group_id="O3" value="15"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Ocular Surface Disease Index (OSDI)</title>
            <description>The Ocular Surface Disease Index (OSDI) is a 12-item questionnaire designed to provide a rapid assessment of the symptoms of ocular irritation consistent with dry eye disease and their impact on vision-related functioning. The 12 items of the OSDI questionnaire are graded on a scale of 0 to 4, where 0 indicates none of the time; 1, some of the time; 2, half of the time; 3, most of the time; and 4, all of the time. The total OSDI score is then calculated on the basis of the following formula: OSDI=[(sum of scores for all questions answered) x 100]/[(total number of questions answered) x 4].
Thus, the OSDI is scored on a scale of 0 to 100, with higher scores representing greater disability. A negative change from baseline indicated an improvement in vision-related functioning.
OSDI was assessed on the Screening Visit, Week 2, Week 6, Week 12, Week 16. Change indicated represents change from Screening to Week 12.</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-13.7" lower_limit="-21.1" upper_limit="-6.4"/>
                  <measurement group_id="O2" value="-2.4" lower_limit="-8.4" upper_limit="3.7"/>
                  <measurement group_id="O3" value="-16.8" lower_limit="-27.9" upper_limit="-5.7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Meibomian Gland Occlusion</title>
        <time_frame>16 Weeks</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Schirmer Without Anesthesia</title>
        <time_frame>16 Weeks</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Schirmer With Anesthesia</title>
        <time_frame>16 Weeks</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrence of Adverse Events</title>
        <time_frame>16 Weeks</time_frame>
        <safety_issue>Yes</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>2.5% IL-1Ra</title>
          <description>Anakinra 2.5% Topical Ophthalmic Solution</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Artificial Tear Topical Ophthalmic Solution</description>
        </group>
        <group group_id="E3">
          <title>5% IL-1Ra</title>
          <description>Anakinra 5% Topical Ophthalmic Solution</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3.3</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Stinging Eye</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Burning Eye</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Grittiness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Itching Eye</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Blurred Vision</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Epiphora</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Discomfort (unspecific)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Eyelid Irritation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Pingueculitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Blepharospasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Episcleritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Reza Dana</name_or_title>
      <organization>Massachusetts Eye and Ear Infirmary</organization>
      <phone>(617) 573-4331</phone>
      <email>Reza_Dana@meei.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
